Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biological Specimen Banks | 4 | 2022 | 55 | 1.070 |
Why?
|
| Retinoblastoma | 3 | 2012 | 117 | 0.690 |
Why?
|
| Biomedical Research | 3 | 2020 | 556 | 0.580 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 77 | 0.440 |
Why?
|
| Retinal Neoplasms | 2 | 2012 | 103 | 0.430 |
Why?
|
| Heart Septal Defects | 2 | 2025 | 44 | 0.410 |
Why?
|
| Picornaviridae | 2 | 2013 | 21 | 0.390 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 88 | 0.380 |
Why?
|
| Antigens, CD | 1 | 2012 | 452 | 0.330 |
Why?
|
| Glycoproteins | 1 | 2012 | 381 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 645 | 0.300 |
Why?
|
| Retina | 1 | 2012 | 502 | 0.290 |
Why?
|
| Peptides | 1 | 2012 | 862 | 0.290 |
Why?
|
| Mitral Valve Stenosis | 1 | 2025 | 39 | 0.240 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 216 | 0.230 |
Why?
|
| Genetic Therapy | 1 | 2007 | 737 | 0.200 |
Why?
|
| Public Opinion | 1 | 2022 | 62 | 0.190 |
Why?
|
| Reoperation | 1 | 2025 | 855 | 0.190 |
Why?
|
| Receptor, Notch4 | 1 | 2020 | 5 | 0.180 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 90 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 1871 | 0.170 |
Why?
|
| Bacillus | 1 | 2000 | 38 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2016 | 871 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 135 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 282 | 0.150 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 399 | 0.150 |
Why?
|
| Progesterone | 1 | 2000 | 635 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 407 | 0.140 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2022 | 272 | 0.140 |
Why?
|
| Down Syndrome | 1 | 2020 | 231 | 0.140 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1879 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 1408 | 0.130 |
Why?
|
| Proteomics | 1 | 2020 | 598 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2025 | 1163 | 0.130 |
Why?
|
| RNA Splicing Factors | 1 | 2016 | 55 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 707 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 34 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 127 | 0.120 |
Why?
|
| Codon, Nonsense | 1 | 2016 | 140 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 148 | 0.120 |
Why?
|
| Myocytes, Cardiac | 2 | 2022 | 676 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2016 | 377 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 1106 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3177 | 0.100 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 39 | 0.100 |
Why?
|
| AC133 Antigen | 1 | 2012 | 37 | 0.100 |
Why?
|
| Genomics | 1 | 2020 | 1669 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 77 | 0.100 |
Why?
|
| Phenotype | 1 | 2022 | 4557 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2911 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2012 | 342 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 4806 | 0.090 |
Why?
|
| Eye Proteins | 1 | 2012 | 233 | 0.090 |
Why?
|
| Humans | 19 | 2025 | 134064 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 157 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 837 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 754 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 585 | 0.080 |
Why?
|
| Mice | 6 | 2013 | 19042 | 0.070 |
Why?
|
| Child | 5 | 2025 | 25840 | 0.070 |
Why?
|
| Glioma | 1 | 2013 | 539 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 352 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 90 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 796 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2006 | 69 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 2538 | 0.060 |
Why?
|
| Cystadenoma, Serous | 1 | 2005 | 7 | 0.060 |
Why?
|
| Azetidines | 1 | 2006 | 64 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 296 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 109 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 59 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2010 | 570 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 673 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 363 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3487 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 746 | 0.060 |
Why?
|
| Phyllodes Tumor | 1 | 2004 | 11 | 0.060 |
Why?
|
| Animals | 6 | 2013 | 36539 | 0.060 |
Why?
|
| Vaginal Neoplasms | 1 | 2004 | 19 | 0.060 |
Why?
|
| Myxoma | 1 | 2004 | 30 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 66 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2004 | 30 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 610 | 0.050 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2003 | 2 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 44 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2003 | 85 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 375 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 55 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2025 | 13049 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2022 | 12 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2004 | 112 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2022 | 11 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 213 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 252 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 468 | 0.040 |
Why?
|
| Androstenedione | 1 | 2000 | 16 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 1 | 2000 | 50 | 0.040 |
Why?
|
| Biotransformation | 1 | 2000 | 56 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 158 | 0.040 |
Why?
|
| Tetralogy of Fallot | 1 | 2022 | 166 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 615 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 217 | 0.040 |
Why?
|
| Monocytes | 1 | 2022 | 360 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2000 | 320 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 389 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 212 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 346 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5206 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 358 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 325 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 1012 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 148 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 835 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 1071 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 925 | 0.030 |
Why?
|
| Infant | 2 | 2025 | 13199 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1316 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2022 | 700 | 0.030 |
Why?
|
| Glucose | 1 | 2000 | 927 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2264 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3729 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 791 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8607 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 443 | 0.030 |
Why?
|
| Female | 7 | 2025 | 71846 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 6604 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 247 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 188 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 28 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2014 | 154 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1126 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 793 | 0.020 |
Why?
|
| Troponin T | 1 | 2014 | 297 | 0.020 |
Why?
|
| Adult | 4 | 2025 | 31961 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2771 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2016 | 804 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 275 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 9916 | 0.020 |
Why?
|
| Male | 3 | 2025 | 66047 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 11164 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 2170 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 258 | 0.020 |
Why?
|
| Adolescent | 2 | 2025 | 20600 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2806 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 4933 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 1598 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2025 | 14836 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1140 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1331 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2025 | 17517 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 2043 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2934 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2006 | 98 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2005 | 128 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 2218 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 194 | 0.010 |
Why?
|
| Mastectomy, Simple | 1 | 2004 | 2 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11748 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 606 | 0.010 |
Why?
|
| Omentum | 1 | 2004 | 48 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1944 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2003 | 51 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2003 | 31 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 100 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2004 | 62 | 0.010 |
Why?
|
| Catalysis | 1 | 2003 | 138 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 970 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3796 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2004 | 229 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 2174 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2858 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 629 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 876 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1440 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 1004 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 3043 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 4877 | 0.010 |
Why?
|
| Middle Aged | 2 | 2005 | 29399 | 0.010 |
Why?
|
| Mutation | 1 | 2006 | 6304 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 7568 | 0.010 |
Why?
|